Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

The Automation Partnership's First Project To Automate Manufacture Of 3D Tissue Constructs
The Automation Partnership (TAP), a world leader in the design and development of innovative advanced automation for life science applications, announced it is collaborating with world leading academics on the prestigious, Technology Strategy Board funded, RAFT (Rapid Automated Fabrication of Tissues) Project to develop and commercialise novel technology for rapid production of 3D tissues, which have the potential to transform drug discovery and regenerative medicine.
generic viagra online
Sapient Delivers New Online Multilingual Re To Support Thousands Of Families Affected By Rare Congenital Syndrome
Sapient (NASDAQ: SAPE) announced that it has designed and delivered a Web-based multilingual solution to support the efforts of CdLS World, an international federation of non-profit organizations committed to assisting those affected by Cornelia de Lange Syndrome (CdLS), a rare congenital disorder. While there is as yet no cure for CdLS, information and access to early therapeutic interventions and therapies is the key to helping children with CdLS reach their full potential. Sapient"s Ask the Doctor - which can be accessed at http://www.cdlsworld.org or through local CdLS country websites - brings a vast online re of up-to-date, relevant medical information to families and medical professionals around the world.
News of the day
Younger Men With Advanced Prostate Cancer Have Shorter Survival Times
While young men with prostate cancer have a low risk of dying early, those with advanced forms of cancer do not live as long as older men with similar forms of the disease. That is the conclusion of a new study published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The paradoxical findings indicate that there may be biological differences between prostate cancers that develop in younger men and those that develop in older men, and that uncovering these differences may help tailor screening and treatment strategies for patients based on age.
Sexual Health

Z-Cube And Yissum Research Development Company Ltd. Sign A Licensing Agreement

Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain. The technology was invented by Professor Elka Touitou from the Department of Pharmaceutics, Faculty of Medicine, at the Hebrew University of Jerusalem. Under the terms of the agreement, Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for pain applications and will sponsor a research program to be conducted by Prof. Touitou and her group. Z-Cube has also received the right to grant sublicenses. Yissum will receive license fees, milestones and royalty payments. "We are pleased to partner with Z-Cube, a world leader in the commercialization of drug delivery technologies," said Yaacov Michlin, CEO of Yissum. "Our novel drug delivery system has the potential to enable relief of both mild and severe pain quickly and efficiently." The work of Prof. Touitou, a worldwide authority in the drug delivery field, focuses on the design of novel carriers for enhanced drug absorption and efficiency. Two start-up companies have been established and are active in the development of various novel pharmaceutical products that are based on her previously-developed innovative technologies. "This innovative drug delivery system is a powerful tool enabling the development of improved medicines for the treatment of pain," said Lorenzo Pradella, Ph.D., Business and Operational Development Director of Z-Cube. "Patients suffering from pain will benefit from this new approach that promises to generate upgraded and easier to use therapeutics." In 2007, the worldwide market for pain management products (excluding over-the-counter products) was approximately $ 4.2 billion, representing one of the largest pharmaceutical segments. The expectation is that the demand for prescription pain management products will continue to grow due to favorable demographics, increasing incidence of chronic pain conditions, and heightened awareness of physicians for the need to treat pain. Improved pain treatment includes not only the discovery and marketing of new chemical entities, such as pain killers, but also the development of new delivery systems devoted to reducing side effects, increasing safety and improving compliance. Yissum Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009